The total return over the past 12 months is -52.51% vs. +16.94% for the S&P 500. So far it's up -33.91% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (52.51%) | (35.66%) | (57.05%) | (36.81%) | (18.85%) | (20.95%) |
| Total Return CAGR | (52.51%) | (35.66%) | (57.05%) | (36.78%) | (18.83%) | (20.94%) |
| Revenue CAGR | (100.00%) | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Inovio Pharmaceuticals, Inc. (INO)
| Year | Start price | End price | INO Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.74 | $1.15 | (33.91%) | +14.51% | (48.42%) |
| 2025 | $1.83 | $1.74 | (4.92%) | +17.72% | (22.64%) |
| 2024 | $6.12 | $1.83 | (70.10%) | +24.89% | (94.99%) |
| 2023 | $18.72 | $6.12 | (67.31%) | +26.19% | (93.50%) |
| 2022 | $59.88 | $18.72 | (68.74%) | (18.17%) | (50.57%) |
| 2021 | $106.20 | $59.88 | (43.62%) | +28.74% | (72.36%) |
| 2020 | $39.60 | $106.20 | +168.18% | +18.37% | +149.81% |
| 2019 | $48.00 | $39.60 | (17.50%) | +31.22% | (48.72%) |
| 2018 | $49.56 | $48.00 | (3.15%) | (4.56%) | +1.41% |
| 2017 | $83.28 | $49.56 | (40.27%) | +21.70% | (61.97%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
